Get the Stockscreener App
3.805
3.18%
0.135
Ardelyx Inc stock is traded at $3.805, with a volume of 1.59M.
It is up +3.18% in the last 24 hours and down -8.31% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$3.67
Open:
$3.71
24h Volume:
1.59M
Relative Volume:
0.31
Market Cap:
$909.19M
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-12.14
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
-4.62%
1M Performance:
-8.31%
6M Performance:
-31.65%
1Y Performance:
-44.80%
1-Day Range:
$3.5701
$3.82
1-Week Range:
$3.5701
$4.06
52-Week Range:
$3.21
$8.06
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
3.80 | 949.84M | 251.85M | -72.58M | -63.80M | -0.3134 |
|
ONC
Beone Medicines Ltd Adr
|
244.98 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.59 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.39 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
488.85 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc.ARDX - WV News
Ardelyx, Inc. (ARDX) Stock Analysis: Investors Eye a Promising 167.99% Upside Potential - DirectorsTalk Interviews
Learn to Evaluate (ARDX) using the Charts - news.stocktradersdaily.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Holdings in Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential - The Globe and Mail
Deutsche Bank AG Boosts Position in Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Ardelyx chief medical officer sells shares worth $26,206 By Investing.com - Investing.com South Africa
Ardelyx CFO sells $29,459 in stock By Investing.com - Investing.com Nigeria
Ardelyx chief medical officer sells shares worth $26,206 - Investing.com Australia
Ardelyx officer Mike Kelliher sells $59,270 in stock By Investing.com - Investing.com South Africa
Ardelyx officer Mike Kelliher sells $59,270 in stock - Investing.com Australia
Ardelyx CFO sells $29,459 in stock - Investing.com
Ardelyx Executives Sell Shares to Cover Taxes - TradingView
Levi & Korsinsky Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - ACCESS Newswire
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 | ARDX Stock News - GuruFocus
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 - The Manila Times
Ardelyx CEO Mike Raab to Share Company Vision at Major Healthcare Conference 2025 - Stock Titan
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ardelyx, Inc.(ARDX) Shareholders - ACCESS Newswire
BNP Paribas Financial Markets Boosts Holdings in Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Director David Mott Acquires 100,000 Shares of Ardelyx Inc (ARDX) - GuruFocus
Ardelyx falls 14% as Q1 results miss on both lines - MSN
Northern Trust Corp Purchases 50,441 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
The Manufacturers Life Insurance Company Sells 130,801 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Benign Growth For Ardelyx, Inc. (NASDAQ:ARDX) Underpins Stock's 28% Plummet - simplywall.st
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. ... - Bluefield Daily Telegraph
Investors Who Lost Money on Ardelyx, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationARDX - ACCESS Newswire
Investors who Lost Money on Ardelyx, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationARDX - ACCESS Newswire
I Have a Prescription for These Two Biopharmas That Fell After Earnings - TheStreet Pro
Cantor Fitzgerald Forecasts Reduced Earnings for Ardelyx - Defense World
Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Ardelyx, Inc. (ARDX) - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx LawsuitARDX - ACCESS Newswire
Ardelyx, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Ardelyx, Inc. (ARDX) - ACCESS Newswire
David Mott Bought 19% More Shares In Ardelyx - simplywall.st
Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
Ardelyx, Inc. Class Action: Levi & Korsinsky Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Ardelyx, Inc.(ARDX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Ardelyx, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – ARDX - ACCESS Newswire
Ardelyx, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationARDX - ACCESS Newswire
Investors who lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
Shareholders that lost money on Ardelyx, Inc. (ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Lost Money on Ardelyx, Inc.(ARDX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders that lost money on Ardelyx, Inc.(ARDX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Ardelyx, Inc. (ARDX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on Ardelyx, Inc.(ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Ardelyx, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationARDX - ACCESS Newswire
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - ACCESS Newswire
Ardelyx, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your RightsARDX - ACCESS Newswire
(ARDX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ardelyx Inc Stock (ARDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Renz Justin A | Chief Financial Officer |
May 20 '25 |
Sale |
4.08 |
7,218 |
29,460 |
416,089 |
| RAAB MICHAEL | President & CEO |
May 20 '25 |
Sale |
4.08 |
46,817 |
191,079 |
1,547,937 |
| Kelliher Mike | See Remarks |
May 20 '25 |
Sale |
4.08 |
14,522 |
59,270 |
282,158 |
| GRAMMER ELIZABETH A | See Remarks |
May 20 '25 |
Sale |
4.08 |
5,992 |
24,456 |
311,731 |
| Foster Eric Duane | Chief Commercial Officer |
May 20 '25 |
Sale |
4.08 |
2,507 |
10,232 |
316,806 |
| MOTT DAVID M | Director |
May 15 '25 |
Buy |
3.29 |
100,000 |
329,120 |
2,496,871 |
| MOTT DAVID M | Director |
May 02 '25 |
Buy |
4.22 |
381,377 |
1,610,936 |
2,396,871 |
| RAAB MICHAEL | President & CEO |
May 02 '25 |
Option Exercise |
0.99 |
20,833 |
20,625 |
1,636,420 |
| RAAB MICHAEL | President & CEO |
May 02 '25 |
Sale |
4.25 |
41,666 |
177,168 |
1,594,754 |
1.76%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):